Atopic dermatitis (AD) is associated with an increased risk of developing other type 2 inflammatory diseases in the affected individuals. However, there is a lack of real-world evidence based on large US commercially insured pediatric populations.

A recent study published in the Journal of the American Academy of Dermatology assessed the prevalence and incidence of type 2 inflammatory diseases (T2D) in pediatric atopic dermatitis (AD) patients using a large US claims database

Assessment for Prevalence was performed for conjunctivitis, rhinitis, urticaria, asthma, eosinophilic esophagitis and chronic rhinosinusitis/nasal polyps, 12 months post-index date.

Also, the 0-2 years old patients were subjected to the evaluation of the incidence of other type 2 inflammatory diseases post-index.

The observations of the study were as follows-

The study enrolled 244,776 AD and matched non-AD patients. 

AD patients demonstrated a higher prevalence and incidence of type 2 inflammatory diseases. 

The prevalence was found to be more than 2 fold for asthma, eosinophilic esophagitis, urticaria, and rhinitis, which further increased with AD severity.

Thus it was concluded that there is a greater burden of type 2 inflammatory diseases in pediatric AD patients, so it is crucial to optimize the management of AD and its numerous associated morbidities.

Source: Journal of the American Academy of Dermatology, 2021, https://doi.org/10.1016/j.jaad.2021.10.038.